Peripheral blood monocyte subsets predict antiviral response in chronic hepatitis C

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 8, 2011, Pages 960-971

  Rodriguez Munoz Y ^a   Martin Vilchez S ^a   Lopez Rodriguez R ^a   Hernandez Bartolome A ^a   Trapero Marugan M ^a   Borque, M J ^a   Moreno Otero, R ^a   Sanz Cameno, P ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; CD14 ANTIGEN; CD16 ANTIGEN; CD31 ANTIGEN; PEGINTERFERON; RIBAVIRIN;

ADULT; AGED; ANGIOGENESIS; ANTIVIRAL ACTIVITY; ARTICLE; CELL INFILTRATION; CELL SUBPOPULATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; MALE; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN MICROARRAY; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GPI-LINKED PROTEINS; HEPATITIS C, CHRONIC; HUMANS; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; MONOCYTES; PREDICTIVE VALUE OF TESTS; RECEPTOR, TIE-2; RECEPTORS, IGG;

EID: 80053203943     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04807.x     Document Type: Article

References (55)

1. Guidotti LG, Chisari FV,. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006; 1: 23-61.
2. Zoulim F, Chevallier M, Maynard M, Trepo C,. Clinical consequences of hepatitis C virus infection. Rev Med Virol 2003; 13: 57-68. (Pubitemid 36125505)
3. Bode JG, Brenndorfer ED, Haussinger D,. Hepatitis C virus (HCV) employs multiple strategies to subvert the host innate antiviral response. Biol Chem 2008; 389: 1283-98.
4. Irshad M, Khushboo I, Singh S,. Hepatitis C virus (HCV): a review of immunological aspects. Int Rev Immunol 2008; 27: 497-517.
5. Shetty S, Lalor PF, Adams DH,. Lymphocyte recruitment to the liver: molecular insights into the pathogenesis of liver injury and hepatitis. Toxicology 2008; 254: 136-46.
6. Chaparro M, Sanz-Cameno P, Trapero-Marugan M, Garcia-Buey L, Moreno-Otero R,. Mechanisms of angiogenesis in chronic inflammatory liver disease. Ann Hepatol 2007; 6: 208-13.
7. Garcia-Monzon C, Sanchez-Madrid F, Garcia-Buey L, Garcia-Arroyo A, Garcia-Sanchez A, Moreno-Otero R,. Vascular adhesion molecule expression in viral chronic hepatitis: evidence of neoangiogenesis in portal tracts. Gastroenterology 1995; 108: 231-41.
8. Medina J, Arroyo AG, Sanchez-Madrid F, Moreno-Otero R,. Angiogenesis in chronic inflammatory liver disease. Hepatology 2004; 39: 1185-95. (Pubitemid 38569038)
9. Noonan DM, De Lerma Barbaro A, Vannini N, Mortara L, Albini A,. Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Rev 2008; 27: 31-40.
10. Anghelina M, Krishnan P, Moldovan L, Moldovan NI,. Monocytes and macrophages form branched cell columns in matrigel: implications for a role in neovascularization. Stem Cells Dev 2004; 13: 665-76. (Pubitemid 40052643)
11. Anghelina M, Krishnan P, Moldovan L, Moldovan NI,. Monocytes/macrophages cooperate with progenitor cells during neovascularization and tissue repair: conversion of cell columns into fibrovascular bundles. Am J Pathol 2006; 168: 529-41. (Pubitemid 43271151)
12. Gordon S,. Do macrophage innate immune receptors enhance atherogenesis? Dev Cell 2003; 5: 666-8. (Pubitemid 37368852)
13. McLean K, Buckanovich RJ,. Myeloid cells functioning in tumor vascularization as a novel therapeutic target. Transl Res 2008; 151: 59-67.
14. Auffray C, Sieweke MH, Geissmann F,. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 2009; 27: 669-92.
15. Glod J, Kobiler D, Noel M, et al. Monocytes form a vascular barrier and participate in vessel repair after brain injury. Blood 2006; 107: 940-6. (Pubitemid 43156290)
16. Tacke F, Randolph GJ,. Migratory fate and differentiation of blood monocyte subsets. Immunobiology 2006; 211: 609-18.
17. Ziegler-Heitbrock HW,. Definition of human blood monocytes. J Leukoc Biol 2000; 67: 603-6.
18. Mizuno K, Toma T, Tsukiji H, et al. Selective expansion of CD16highCCR2-subpopulation of circulating monocytes with preferential production of haem oxygenase (HO)-1 in response to acute inflammation. Clin Exp Immunol 2005; 142: 461-70. (Pubitemid 41719842)
19. Ziegler-Heitbrock L,. The CD14 + CD16 + blood monocytes: their role in infection and inflammation. J Leukoc Biol 2007; 81: 584-92. (Pubitemid 46393535)
20. Urra X, Villamor N, Amaro S, et al. Monocyte subtypes predict clinical course and prognosis in human stroke. J Cereb Blood Flow Metab 2009; 29: 994-1002.
21. De Palma M, Venneri MA, Galli R, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005; 8: 211-26. (Pubitemid 41317592)
22. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001; 7: 1194-201. (Pubitemid 33063774)
23. Nasarre P, Thomas M, Kruse K, et al. Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res 2009; 69: 1324-33.
24. Venneri MA, De Palma M, Ponzoni M, et al. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 2007; 109: 5276-85. (Pubitemid 46890548)
25. De Palma M, Murdoch C, Venneri MA, Naldini L, Lewis CE,. Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol 2007; 28: 519-24.
26. De Palma M, Naldini L,. Tie2-expressing monocytes (TEMs): novel targets and vehicles of anticancer therapy? Biochim Biophys Acta 2009; 1796: 5-10.
27. Ribatti D,. The paracrine role of Tie-2-expressing monocytes in tumor angiogenesis. Stem Cells Dev 2009; 18: 703-6.
28. Makinde T, Agrawal DK,. Intra and extravascular transmembrane signalling of angiopoietin-1-Tie2 receptor in health and disease. J Cell Mol Med 2008; 12: 810-28. (Pubitemid 351718065)
29. Fiedler U, Augustin HG,. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 2006; 27: 552-8. (Pubitemid 44780853)
30. Fingerle G, Pforte A, Passlick B, Blumenstein M, Strobel M, Ziegler-Heitbrock HW,. The novel subset of CD14 + /CD16 + blood monocytes is expanded in sepsis patients. Blood 1993; 82: 3170-6. (Pubitemid 23334947)
31. Ancuta P, Rao R, Moses A, et al. Fractalkine preferentially mediates arrest and migration of CD16 + monocytes. J Exp Med 2003; 197: 1701-7. (Pubitemid 36745345)
32. Grip O, Bredberg A, Lindgren S, Henriksson G,. Increased subpopulations of CD16(+) and CD56(+) blood monocytes in patients with active Crohn's disease. Inflamm Bowel Dis 2007; 13: 566-72. (Pubitemid 46799640)
33. Lewis CE, Hughes R,. Inflammation and breast cancer. Microenvironmental factors regulating macrophage function in breast tumours: hypoxia and angiopoietin-2. Breast Cancer Res 2007; 9: 209.
34. Pulaski HL, Spahlinger G, Silva IA, et al. Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. J Transl Med 2009; 7: 49.
35. Skrzeczynska-Moncznik J, Bzowska M, Loseke S, Grage-Griebenow E, Zembala M, Pryjma J,. Peripheral blood CD14high CD16 + monocytes are main producers of IL-10. Scand J Immunol 2008; 67: 152-9.
36. Zimmermann HW, Seidler S, Nattermann J, et al. Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS ONE 2010; 5: e11049.
37. Nowak G, Karrar A, Holmen C, et al. Expression of vascular endothelial growth factor receptor-2 or Tie-2 on peripheral blood cells defines functionally competent cell populations capable of reendothelialization. Circulation 2004; 110: 3699-707. (Pubitemid 39665260)
38. Pucci F, Venneri MA, Biziato D, et al. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood 2009; 114: 901-14.
39. Gabriel A, Kukla M, Wilk M, Liszka L, Petelenz M, Musialik J,. Angiogenesis in chronic hepatitis C is associated with inflammatory activity grade and fibrosis stage. Pathol Res Pract 2009; 205: 758-64.
40. Sanz-Cameno P, Martin-Vilchez S, Rodriguez-Munoz Y, et al. Intrahepatic angiopoietin-2 protein expression modulation by hepatitis C virus: MAPK, PI3K and reactive oxygen species (ROS) implication. J Hepatol 2008; 48: S230-1.
41. Murdoch C, Tazzyman S, Webster S, Lewis CE,. Expression of Tie-2 by human monocytes and their responses to angiopoietin-2. J Immunol 2007; 178: 7405-11. (Pubitemid 46847468)
42. Sanz-Cameno P, Martin-Vilchez S, Lara-Pezzi E, et al. Hepatitis B virus promotes angiopoietin-2 expression in liver tissue: role of HBV x protein. Am J Pathol 2006; 169: 1215-22. (Pubitemid 351194358)
43. Figueroa-Vega N, Sanz-Cameno P, Moreno-Otero R, Sanchez-Madrid F, Gonzalez-Amaro R, Marazuela M,. Serum levels of angiogenic molecules in autoimmune thyroid diseases and their correlation with laboratory and clinical features. J Clin Endocrinol Metab 2009; 94: 1145-53.
44. Scharpfenecker M, Fiedler U, Reiss Y, Augustin HG,. The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci 2005; 118 (Pt 4): 771-80. (Pubitemid 40372585)
45. Fukuhara S, Sako K, Noda K, Nagao K, Miura K, Mochizuki N,. Tie2 is tied at the cell-cell contacts and to extracellular matrix by angiopoietin-1. Exp Mol Med 2009; 41: 133-9.
46. Thomas M, Augustin HG,. The role of the Angiopoietins in vascular morphogenesis. Angiogenesis 2009; 12: 125-37.
47. Mas VR, Maluf DG, Archer KJ, Yanek KC, Fisher RA,. Angiogenesis soluble factors as hepatocellular carcinoma noninvasive markers for monitoring hepatitis C virus cirrhotic patients awaiting liver transplantation. Transplantation 2007; 84: 1262-71. (Pubitemid 351339314)
48. Salcedo Mora X, Sanz-Cameno P, Medina J, et al. Association between angiogenesis soluble factors and disease progression markers in chronic hepatitis C patients. Rev Esp Enferm Dig 2005; 97: 699-706. (Pubitemid 44323957)
49. Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP,. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer 2007; 43: 979-92. (Pubitemid 46483030)
50. Torimura T, Ueno T, Kin M, et al. Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. J Hepatol 2004; 40: 799-807. (Pubitemid 38507361)
51. Martin-Vilchez S, Rodriguez-Munoz Y, Lopez-Rodriguez R, et al. Hepatitis C virus promotes human hepatic stellate cells migration. J Hepatol 2009; 50: S949-50.
52. Medina J, Sanz-Cameno P, Garcia-Buey L, Martin-Vilchez S, Lopez-Cabrera M, Moreno-Otero R,. Evidence of angiogenesis in primary biliary cirrhosis: an immunohistochemical descriptive study. J Hepatol 2005; 42: 124-31. (Pubitemid 40038910)
53. Novo E, Cannito S, Zamara E, et al. Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. Am J Pathol 2007; 170: 1942-53. (Pubitemid 47339268)
54. Huang H, Bhat A, Woodnutt G, Lappe R,. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 2010; 10: 575-85.
55. Sanz-Cameno P, Trapero-Marugan M, Chaparro M, Jones EA, Moreno-Otero R,. Angiogenesis: from chronic liver inflammation to hepatocellular carcinoma. J Oncol 2010; 2010: 272170.